• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

    3/12/24 8:11:02 AM ET
    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Utilities
    Get the next $ACAD alert in real time by email

    Shares of Oracle Corporation (NYSE:ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fiscal third quarter.

    Oracle’s third-quarter revenue increased 7% year-over-year to $13.3 billion, which missed the consensus estimate of $13.306 billion, according to Benzinga Pro. The company reported quarterly earnings of $1.41 per share, which beat average estimates of $1.38 per share.

    Oracle shares jumped 13.4% to $129.46 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Singularity Future Technology Ltd. (NASDAQ:SGLY) gained 88.6% to $5.94 in pre-market trading after gaining over 6% on Monday.
    • Nukkleus Inc. (NASDAQ:NUKK) shares rose 87.8% to $2.16 in pre-market trading after surging over 43% on Monday.
    • ClearOne, Inc. (NASDAQ:CLRO) rose 74.4% to $1.58 in pre-market trading. ClearOne announced a special one-time cash dividend of 50 cents per share.
    • Assure Holdings Corp. (NASDAQ:IONM) gained 49.6% to $0.49 in pre-market trading. Assure Holdings entered into an agreement to sell certain of its assets to MPOWERHealth for up to $4.5 million.
    • Gaucho Group Holdings, Inc. (NASDAQ:VINO) climbed 31.4% to $0.71 in pre-market trading.
    • Heritage Insurance Holdings, Inc. (NYSE:HRTG) shares gained 24.6% to $8.91 in pre-market trading following better-than-expected fourth-quarter results.
    • Nexalin Technology, Inc. (NASDAQ:NXL) shares gained 18.7% to $0.5010 in pre-market trading after falling 12% on Monday. Nexalin Technology recently announced results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia.
    • ATRenew Inc. (NYSE:RERE) gained 15.1% to $1.37 in pre-market trading after the company reported fourth-quarter results and announced a $20 million share repurchase program.
    • MINISO Group Holding Limited (NASDAQ:MNSO) shares gained 15% to $20.61 in pre-market trading after posting stronger-than-expected quarterly earnings.

    Losers

    • Renalytix Plc (NASDAQ:RNLX) fell 19.3% to $0.92 pre-market trading after gaining around 5% on Monday. Renalytix recently received an unsolicited acquisition approach from a large, publicly-listed strategic diagnostics company and is evaluating an acquisition of the entire issued, and to be issued, the share capital of the company.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares dipped 18.3% to $2.05 in pre-market trading following fourth-quarter results.
    • ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) fell 17.4% to $19.93 in pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.
    • Finch Therapeutics Group, Inc. (NASDAQ:FNCH) dipped 16.5% to $2.85 in pre-market trading after jumping over 36% on Monday.
    • Snow Lake Resources Ltd. (NASDAQ:LITM) fell 13% to $0.80 pre-market trading after declining around 6% on Monday.
    • Solidion Technology Inc. (NASDAQ:STI) fell 12.6% to $1.53 in pre-market trading after jumping 124% on Monday.
    • Safe and Green Development Corporation (NASDAQ:SGD) declined 12.1% to $1.02 in pre-market trading after falling over 6% on Monday.
    • Kidpik Corp. (NASDAQ:PIK) shares tumbled 10.8% to $4.34 after surging 80% on Monday.
    • Marpai, Inc. (NASDAQ:MRAI) shares tumbled 10.2% to $1.76 in pre-market trading after gaining over 11% on Monday. Marpai shares are trading higher after the company reported better-than-expected preliminary Q4 net revenue results. Also, the company announced an "Off-Cycle" new client agreement.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 5.9% to $9.16 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.

     

    Now Read This: Kohl's, Oracle And 3 Stocks To Watch Heading Into Tuesday

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $CLRO
    $CTMX
    $FNCH

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    2/25/2026$185.00Perform → Outperform
    Oppenheimer
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    Oracle Corporation
    $ORCL
    2/9/2026Buy → Hold
    Melius
    Oracle Corporation
    $ORCL
    2/9/2026$180.00Neutral → Buy
    DA Davidson
    Oracle Corporation
    $ORCL
    2/4/2026$270.00 → $205.00Outperform
    BMO Capital Markets
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Oracle Corporation
    $ORCL
    1/12/2026$240.00Buy
    Goldman
    More analyst ratings

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    SEC Filings

    View All

    SEC Form 6-K filed by MINISO Group Holding Limited

    6-K - MINISO Group Holding Ltd (0001815846) (Filer)

    3/6/26 8:00:59 AM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 6-K filed by ATRenew Inc.

    6-K - ATRenew Inc. (0001838957) (Filer)

    3/6/26 6:13:31 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    ClearOne Inc. (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CLEARONE INC (0000840715) (Filer)

    3/5/26 4:30:23 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner First Finance Ltd. bought $1,750,000 worth of shares (437,500 units at $4.00), increasing direct ownership by 36% to 1,641,162 units (SEC Form 4)

    4 - CLEARONE INC (0000840715) (Issuer)

    3/6/26 6:02:39 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    Officer Dugel Pravin sold $166,064 worth of shares (20,056 units at $8.28), decreasing direct ownership by 0.66% to 3,013,022 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:20:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $23,267 worth of shares (2,810 units at $8.28), decreasing direct ownership by 1% to 269,108 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:19:11 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATRenew Inc. Announces Appointment of New Director

    SHANGHAI, March 6, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE:RERE), a pioneer in technology-driven recycling and trade-in solutions for consumer products in China, today announced that Mr. Yue Teng has been appointed as a new member of the Company's board of directors (the "Board") and the compensation committee of the Board, and Ms. Rui Zhu has been appointed as a new member of the nominating and corporate governance committee of the Board, effective immediately, to fill the vacancies arising from the resignation of Mr. Mervin Ye Zhou. Upon the appointment of Mr. Yue Teng, the Board consists of eight members: Mr. Kerry Xuefeng Chen, Mr. Yongliang Wang, Mr. Chen Ch

    3/6/26 3:00:00 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    Snow Lake's Portfolio Company, Kadmos Energy, Submits Response to the Texas Advanced Nuclear Energy Office's Request for Information

    Winnipeg, Manitoba--(Newsfile Corp. - March 5, 2026) - Snow Lake Resources Ltd., d/b/a Snow Lake Energy (NASDAQ:LITM) ("Snow Lake"), a nuclear fuel cycle company, announces that following its public debut at the Texas Nuclear Summit[1] in October 2025, Snow Lake's small modular reactor portfolio company, Kadmos Energy Services LLC ("Kadmos"), has responded to Texas' call for nuclear power expansion via the Texas Advanced Nuclear Energy Office ("TANEO") Request for Information ("RFI") process. Kadmos' response outlines how Texas can help accelerate the deployment of new nuclear power generation, while anticipating fuel cycle considerations that will be crucial to its success.Shaping the Texa

    3/5/26 8:30:00 AM ET
    $LITM
    Other Metals and Minerals
    Basic Materials

    Oracle Transforms Construction Safety Management with AI

    AI-enabled predictive intelligence solution helps organizations avoid safety incidents, reduce costs, and foster a proactive safety cultureAUSTIN, Texas, March 5, 2026 /PRNewswire/ -- Oracle today announced the general availability of Oracle Construction and Engineering Advisor for Safety, an AI-enabled predictive intelligence solution that transforms safety management. With the offering, construction firms can better forecast project safety incidents to proactively prevent accidents, and support safer, more cost-effective jobsites. Previously, creating accurate predictive model

    3/5/26 7:45:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner First Finance Ltd. bought $1,750,000 worth of shares (437,500 units at $4.00), increasing direct ownership by 36% to 1,641,162 units (SEC Form 4)

    4 - CLEARONE INC (0000840715) (Issuer)

    3/6/26 6:02:39 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Sc Capital Ii Sponsor Llc bought $2,550,000 worth of Class A ordinary shares (255,000 units at $10.00) (SEC Form 4)

    4 - Nukkleus Inc. (0001787518) (Reporting)

    12/1/25 5:20:47 PM ET
    $NUKK
    Professional Services
    Consumer Discretionary

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oracle upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Oracle from Perform to Outperform and set a new price target of $185.00

    2/25/26 7:38:35 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

    2/24/26 7:44:56 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Leadership Updates

    Live Leadership Updates

    View All

    ATRenew Inc. Announces Appointment of New Director

    SHANGHAI, March 6, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE:RERE), a pioneer in technology-driven recycling and trade-in solutions for consumer products in China, today announced that Mr. Yue Teng has been appointed as a new member of the Company's board of directors (the "Board") and the compensation committee of the Board, and Ms. Rui Zhu has been appointed as a new member of the nominating and corporate governance committee of the Board, effective immediately, to fill the vacancies arising from the resignation of Mr. Mervin Ye Zhou. Upon the appointment of Mr. Yue Teng, the Board consists of eight members: Mr. Kerry Xuefeng Chen, Mr. Yongliang Wang, Mr. Chen Ch

    3/6/26 3:00:00 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to

    3/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oracle Sets the Date for its Third Quarter Fiscal Year 2026 Earnings Announcement

    Earnings Results to be released on March 10, 2026, After the Close of the MarketAUSTIN, Texas, March 3, 2026 /PRNewswire/ -- Oracle Corporation today announced that its third quarter fiscal year 2026 results will be released on Tuesday, March 10th, after the close of the market. Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About OracleOracle offers integrated suites of applications plus secure, autonomous infr

    3/3/26 4:00:00 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    ATRenew to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

    SHANGHAI, Feb. 25, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE:RERE), a pioneer in the technology-driven trade-in solutions and circular economy for consumer products in China, today announced that it plans to release its unaudited financial results for the fourth quarter and full year of 2025 before the U.S. market opens on Wednesday, March 11, 2026. The Company's management will hold an earnings conference call at 08:00 A.M. Eastern Time on Wednesday, March 11, 2026 (08:00 P.M. Beijing Time on the same day) to discuss the financial results. Listeners may access the call by dialing the following numbers:International:1-412-317-6061United States Toll Free:1-888-317-6

    2/25/26 3:00:00 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    $ACAD
    $CLRO
    $CTMX
    $FNCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care